(287 days)
Western Blot
Not Found
No
The device description details a standard ELISA assay which relies on chemical reactions and photometric measurement, not AI/ML algorithms. There are no mentions of AI, ML, or related concepts in the document.
No
This device is an in vitro diagnostic (IVD) test, specifically an ELISA kit, intended for the qualitative detection of antibodies to aid in the presumptive diagnosis of HSV infection. It does not provide treatment or therapy.
Yes
This device is an Enzyme-linked Immunosorbent Assay (ELISA) intended for qualitatively detecting human IgG class antibodies to HSV-2 in human serum, which is used "for aiding in the presumptive diagnosis of HSV infection." This explicitly states its use in diagnosis.
No
The device description clearly outlines a physical kit involving reagents, microtiter wells, and photometric measurement, which are hardware components, not software.
Yes, this device is an IVD (In Vitro Diagnostic).
Here's why:
- Intended Use: The intended use explicitly states it is for "qualitatively detecting the presence or absence of human IgG class antibodies to HSV-2 in human serum." This involves testing a sample taken from the human body in vitro (outside the body) to provide information about a person's health status (presence of antibodies indicating potential infection).
- Device Description: The description details an "Enzyme-Linked Immunosorbent Assay (ELISA) for the qualitative determination of IgG antibodies in human serum." This is a standard laboratory technique performed on biological samples in vitro.
- Sample Type: The device uses "human serum," which is a biological specimen obtained from a patient.
- Purpose: The test is intended to "aid in the presumptive diagnosis of HSV infection," which is a diagnostic purpose.
All of these characteristics align with the definition of an In Vitro Diagnostic device.
N/A
Intended Use / Indications for Use
The Trinity Biotech Captia™ Herpes Simplex Virus (HSV) 2 Type Specific IgG kit is an Enzyme-linked Immunosorbent Assay (ELISA) intended for qualitatively detecting the presence or absence of human IgG class antibodies to HSV-2 in human serum. In conjunction with the Trinity Biotech Captia™ Herpes Simplex Virus (HSV) I Type Specific IgG kit, the test is indicated for testing sexually active adults or expectant mothers for aiding in the presumptive diagnosis of HSV infection. Due to the implications of positive results, it is recommended they be confirmed in a low prevalence population with Western blot. The performance of this assay has not been established for use in a pediatric population, for neonatal screening, for testing of immunocompromised patients, or for use with automated equipment. The user is responsible for establishing assay performance in these populations and with automated equipment.
Product codes
MYF
Device Description
The CaptiaTM HSV 2 IgG Type Specific kit is an Enzyme-Linked Immunosorbent Assay (ELISA) for the qualitative determination of IgG antibodies in human serum to Herpes simplex Type 2 antigen. The Captia™ HSV 2 IgG Type Specific assay may be used as an aid in the diagnoses of Herpes infection For In Vitro Diagnostic Use Only.
The Captia™ HSV 2 IgG Type Specific test is an Enzyme-Linked Immunosorbent assay to detect IgG antibodies to Herpes simplex 2 antigen. Purified recombinant HSV gG2 antigen is attached to a solid phase microtiter well. Diluted test sera is added to each well. If the antibodies are present that recognize the antigen, they will bind to the antigen in the well. After incubation, the wells are washed to remove unbound antibody. An enzyme labeled anti-human IgG is added to each well. If antibody is present, it will bind to the antibody attached to the antigen on the well. After incubation, the wells are washed to remove unbound conjugate. A substrate solution is added to each well. If enzyme is present, the substrate will undergo a color change. After an incubation period, the reaction is stopped and the color intensity is measured photometrically, producing an indirect measurement of specific antibody in the patient specimen.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Not Found
Indicated Patient Age Range
Sexually active adults or expectant mothers. Not established for use in a pediatric population.
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
An outside investigator assessed the % agreement negative with consented, coded, unselected, banked and masked sera from expectant mothers (n = 210). The reference method was an HSV 2 Western Blot (WB) from a Pacific Northwest university. Of 43 WB positives: Trinity ELISA was 43 positive. Of 165 WB negatives: Trinity ELISA was 151 negative, 13 positive and 1 equivocal.
An outside investigator assessed the % agreement positive and % agreement negative with consented, unselected and masked sera from sexually active adults over the age of 14 (n = 198). The reference method was an HSV 2 Western Blot (WB) from a Pacific Northwest university. Of 61 WB positives: Trinity ELISA was 59 positive and 2 negative. Of 134 WB negatives: Trinity ELISA was 121 negative and 13 positive.
An outside investigator assessed the % agreement positive and % agreement negative with unselected, banked and masked sera from a low prevalence population (n = 184). The reference method was an HSV 2 Western Blot (WB) from a Pacific Northwest university. Of 179 WB negatives: Trinity ELISA was 163 negative, 14 positive and 2 equivocal. Of 4 WB positives: Trinity ELISA was 4 positive.
An outside investigator assessed the % agreement positive using unselected, retrospective and masked sera from patients that were at least six weeks but not more than one year post clinical presentation and culture HSV 2 positive (n = 56). Reference methods included culture (infection) and an HSV 2 Western Blot (WB) (antibody) from a Pacific Northwest university. Of 56 culture positives: 1) Trinity ELISA was 56 positive and, 2) WB was 55 positive and 1 negative.
An outside investigator at a Pacific Northwest University assessed the % agreement positive of the Trinity Biotech Captia™ HSV 2 Type Specific IgG kit and alternate HSV 2 type specific IgG ELISA test with 200 prospective, unselected, sequentially submitted specimens.
An outside investigator at a Pacific Northwest University assessed the type specificity using HSV 1 Western Blot positive and HSV 2 Western Blot negative sera from the above described populations (n = 292); expectant mothers, sexually active adults, low prevalence persons, and HSV 1 culture positives. Of 292 HSV 1 Western Blot positive and HSV 2 Western Blot negative samples: ELISA was 265 negative, 23 positive and 4 equivocal.
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
Performance Characteristics % Agreement Positive and % Agreement Negative with Expectant Mothers: n = 210.
% agreement positive to WB: 100.00% (43/43), 95% CI: 91.8-100.0%.
% agreement negative to WB: 91.52% (151/165), 95% CI: 86.2-95.3%.
% Agreement Positive and % Agreement Negative with Sexually Active Adults: n = 198.
% agreement positive to WB: 96.72% (59/61), 95% CI: 88.7-99.6%.
% agreement negative to WB: 90.30% (121/134), 95% CI: 84.0-94.7%.
% Agreement Positive and % Agreement Negative with a Low Prevalence Population: n = 184.
% agreement positive to WB: 100.00% (4/4), 95% CI: 39.8-100.0%.
% agreement negative to WB: 91.06% (163/179), 95% CI: 85.9-94.8%.
% Agreement Positive with Culture Positives: n = 56.
% agreement positive to culture: 100.00% (56/56), 95% CI: 93.6-100.0%.
% agreement positive to WB: 100.00% (55/55), 95% CI: 93.5-100.0%.
% Agreement Positive and % Agreement Negative with Alternate HSV 2 Type Specific IgG ELISA: n = 200.
Percent Positive Agreement: 97.14% (68 / 70), 95% CI: 90.1 – 99.7%.
Percent Negative Agreement: 92.13% (117 / 127), 95% CI: 86.0 – 96.2%.
Percent Agreement: 92.50% (185 / 200), 95% CI: 87.9 – 95.7%.
Type Specificity with HSV 1 Western Blot Positives: n = 292.
Type-specificity relative to WB: 90.75% (265/292), 95% CI: 86.8-93.8%.
Type cross-reactivity relative to WB: 8.0% (23/292), 95% CI: 5.06-11.6%.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found. Values represented as percent agreement.
Predicate Device(s)
Western Blot
Reference Device(s)
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information
Not Found
§ 866.3305 Herpes simplex virus serological assays.
(a)
Identification. Herpes simplex virus serological assays are devices that consist of antigens and antisera used in various serological tests to identify antibodies to herpes simplex virus in serum. Additionally, some of the assays consist of herpes simplex virus antisera conjugated with a fluorescent dye (immunofluorescent assays) used to identify herpes simplex virus directly from clinical specimens or tissue culture isolates derived from clinical specimens. The identification aids in the diagnosis of diseases caused by herpes simplex viruses and provides epidemiological information on these diseases. Herpes simplex viral infections range from common and mild lesions of the skin and mucous membranes to a severe form of encephalitis (inflammation of the brain). Neonatal herpes virus infections range from a mild infection to a severe generalized disease with a fatal outcome.(b)
Classification. Class II (special controls). The device is classified as class II (special controls). The special control for the device is FDA's revised guidance document entitled “Class II Special Controls Guidance Document: Herpes Simplex Virus Types 1 and 2 Serological Assays.” For availability of the guidance revised document, see § 866.1(e).
0
JUL 1 3 2004
Summary of Safety and Effectiveness Information Captia™ HSV 2 IgG Type Specific ELISA Test Kit
- I. Trinity Biotech USA 2823 Girts Rd. Jamestown, NY 14701 Contact Person: Bonnie B. DeJov Telephone: 716-483-3851 Date of Preparation: July 9, 2004
II. Description of Device
The CaptiaTM HSV 2 IgG Type Specific kit is an Enzyme-Linked Immunosorbent Assay (ELISA) for the qualitative determination of IgG antibodies in human serum to Herpes simplex Type 2 antigen. The Captia™ HSV 2 IgG Type Specific assay may be used as an aid in the diagnoses of Herpes infection
For In Vitro Diagnostic Use Only.
The Captia™ HSV 2 IgG Type Specific test is an Enzyme-Linked Immunosorbent assay to detect IgG antibodies to Herpes simplex 2 antigen. Purified recombinant HSV gG2 antigen is attached to a solid phase microtiter well. Diluted test sera is added to each well. If the antibodies are present that recognize the antigen, they will bind to the antigen in the well. After incubation, the wells are washed to remove unbound antibody. An enzyme labeled anti-human IgG is added to each well. If antibody is present, it will bind to the antibody attached to the antigen on the well. After incubation, the wells are washed to remove unbound conjugate. A substrate solution is added to each well. If enzyme is present, the substrate will undergo a color change. After an incubation period, the reaction is stopped and the color intensity is measured photometrically, producing an indirect measurement of specific antibody in the patient specimen.
III. Predicate Device
The Captia™ HSV 2 IgG Type Specific test is substantially equivalent to Western Blot. Equivalence is demonstrated by the following comparative results:
1
Perfomance Characteristics % Agreement Positive and % Agreement Negative with Expectant Motherst
An outside investigator assessed the % agreement negative with consented, coded, unselected, banked and masked sera from expectant mothers (n = 210). The reference method was an HSV 2 Western Blot (WB) from a Pacific Northwest university. Of 43 WB positives: Trinity ELISA was 43 positive. Of 165 WB negatives: Trinity ELISA was 151 negative, 13 positive and 1 equivocal.
| % Agreement Positive and % Agreement Negative with Expectant Mothers (n = 210)† | ||
|---|---|---|
| Characteristic | % (EL/WB)* | 95% Confidence Interval (CI) |
| % agreement positive to WB | 100.00% (43/43) | 91.8-100.0% |
| % agreement negative to WB | 91.52% (151/165) | 86.2-95.3% |
| * Excludes one atypical Western Blot and one sample that was both atypical Western Blot and ELISA equivocal. | ||
| † The word “% agreement” refers to comparing this assay's results with those of a similar assay. No attempt was made to correlate the assay results to disease presence or absence. No judgment can be made on the similar assay's accuracy in predicting disease. |
% Agreement Positive and % Agreement Negative with Sexually Active Adults t
An outside investigator assessed the % agreement positive and % agreement negative with consented, unselected and masked sera from sexually active adults over the age of 14 (n = 198). The reference method was an HSV 2 Western Blot (WB) from a Pacific Northwest university. Of 61 WB positives: Trinity ELISA was 59 positive and 2 negative. Of 134 WB negatives: Trinity ELISA was 121 negative and 13 positive.
% Agreement Positive and % Agreement Negative with Sexually Active Adults (n = 198)†
| Characteristic | % (EL/WB)* | 95% Confidence Interval (CI) |
|---|---|---|
| % agreement positive to WB | 96.72% (59/61) | 88.7-99.6% |
| % agreement negative to WB | 90.30% (121/134) | 84.0-94.7% |
Excludes three atypical Western Blot.
† The word "% agreement" refers to comparing this assay's results with those of a similar assay. No attempt was made to correlate the assay results to disease presence or absence. No judgment can be made on the similar assay's accuracy in predicting disease.
% Agreement Positive and % Agreement Negative with a Low Prevalence Populationt
An outside investigator assessed the % agreement positive and % agreement negative with unselected, banked and masked sera from a low prevalence population (n = 184). The reference method was an HSV 2 Western Blot (WB) from a Pacific Northwest university. Of 179 WB negatives: Trinity ELISA was 163 negative, 14 positive and 2 equivocal. Of 4 WB positives: Trinity ELISA was 4 positive.
% Agreement Positive and % Agreement Negative with a Low Prevalence Population (n = 184)†
| Characteristic | % (EL/WB)* | 95% Confidence Interval (CI) |
|---|---|---|
| % agreement positive to WB | 100.00% (4/4) | 39.8-100.0% |
| % agreement negative to WB | 91.06% (163/179) | 85.9-94.8% |
- Excludes one atypical Western Blot.
t The word "% agreement" refers to comparing this assay's results with those of a similar assay. No attempt was made to correlate the assay results to disence. No judgment can be made on the similar assure its armilar assay s accuracy in predicting disease.
2
% Agreement Positive with Culture Positivest
An outside investigator assessed the % agreement positive using unselected, retrospective and masked sera from patients that were at least six weeks but not more than one year post clinical presentation and culture HSV 2 positive (n = 56). Reference methods included culture (infection) and an HSV 2 Western Blot (WB) (antibody) from a Pacific Northwest university. Of 56 culture positives: 1) Trinity ELISA was 56 positive and, 2) WB was 55 positive and 1 negative.
% Agreement Positive with Culture Positives (n = 56)t
| Characteristic | % (EL/WB or Culture) | 95% Confidence Interval (CI) |
|---|---|---|
| % agreement positive to culture | 100.00% (56/56) | 93.6-100.0% |
| % agreement positive to WB | 100.00% (55/55) | 93.5-100.0% |
| † The word "% agreement" refers to comparing this assay's results with those of a similar assay. No attempt was made to | ||
| correlate the assay results to disease presence or absence. No judgment can be made on the similar assay's accuracy in | ||
| predicting disease. |
% Agreement Positive and % Agreement Negative with Alternate HSV 2 Type Specific IgG ELISA
An outside investigator at a Pacific Northwest University assessed the % agreement positive of the Trinity Biotech Captia™ HSV 2 Type Specific IgG kit and alternate HSV 2 type specific IgG ELISA test with 200 prospective, unselected, sequentially submitted specimens.
| Prospectively Collected, Sequential
Sera | Alternate HSV 2 Type Specific
IgG | | | |
|-------------------------------------------------|--------------------------------------|----|-----|---|
| | + | - | E | |
| Trinity Biotech CaptiaTM
HSV 2 Type Specific | + | 68 | 10 | 2 |
| | - | 2 | 117 | 0 |
| | E | 0 | 1 | 0 |
| Characteristic | % (TBU ELISA / Alt. ELISA) | 95% Confidence Interval (CI) |
|---|---|---|
| Percent Positive Agreement | 97.14% (68 / 70) | 90.1 – 99.7% |
| Percent Negative Agreement | 92.13% (117 / 127) | 86.0 – 96.2% |
| Percent Agreement | 92.50% (185 / 200) | 87.9 – 95.7% |
Type Specificity with HSV 1 Western Blot Positives
An outside investigator at a Pacific Northwest University assessed the type specificity using HSV 1 Western Blot positive and HSV 2 Western Blot negative sera from the above described populations (n = 292); expectant mothers, sexually active adults, low prevalence persons, and HSV 1 culture positives. Of 292 HSV 1 Western Blot positive and HSV 2 Western Blot negative samples: ELISA was 265 negative, 23 positive and 4 equivocal.
| Characteristic | % (EL/WB) | 95% Confidence Interval (CI) |
|---|---|---|
| Type-specificity relative to WB | 90.75% (265/292) | 86.8-93.8% |
| Type cross-reactivity relative to WB | 8.0% (23/292) | 5.06-11.6% |
Type Specificity with HSV 2 Western Blot Positives (n = 292)
3
Public Health Service
Image /page/3/Picture/2 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a stylized caduceus symbol, which is a staff with two snakes coiled around it, and the words "DEPARTMENT OF HEALTH & HUMAN SERVICES USA" arranged in a circular pattern around the symbol. The caduceus is a common symbol associated with healthcare and medicine.
Food and Drug Administration 2098 Gaither Road Rockville MD 20850
JUL 1 3 2004
Ms. Bonnie B. DeJoy Director of Quality Systems Trinity Biotech USA 2823 Girts Road Jamestown, NY 14701
K033106 Re:
Trade/Device Name: CaptiaTM HSV2 IgG Type Specific ELISA Regulation Number: 21 CFR 866.3305 Regulation Name: Herpes Simplex Virus Serological Reagents Regulatory Class: Class III Product Code: MYF Dated: April 20, 2004 Received: April 21, 2004
Dear Ms. DeJoy:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820).
4
Page 2
This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.
If you desire specific information about the application of labeling requirements to your device, or questions on the promotion and advertising of your device, please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (301) 594-3084. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/dsma/dsmamain.html.
Sincerely yours,
Salartys
Sally A. Hojvat, M.Sc., Ph.D. Director Division of Microbiology Devices Office of In Vitro Diagnostic Device Evaluation and Safety Center for Devices and Radiological Health
Enclosure
5
510(k) Number: K033106 Device Name: Captia™ HSV2 IgG Type Specific ELISA
Indications for Use:
The Trinity Biotech Captia™ Herpes Simplex Virus (HSV) 2 Type Specific IgG kit is an Enzyme-linked Immunosorbent Assay (ELISA) intended for qualitatively detecting the presence or absence of human IgG class antibodies to HSV-2 in human serum. In conjunction with the Trinity Biotech Captia™ Herpes Simplex Virus (HSV) I Type Specific IgG kit, the test is indicated for testing sexually active adults or expectant mothers for aiding in the presumptive diagnosis of HSV infection. Due to the implications of positive results, it is recommended they be confirmed in a low prevalence population with Western blot. The performance of this assay has not been established for use in a pediatric population, for neonatal screening, for testing of immunocompromised patients, or for use with automated equipment. The user is responsible for establishing assay performance in these populations and with automated equipment.
Prescription Use ✔ (Part 21 CFR 801 Subpart D)
.. .. .. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
AND/OR
Over-The Counter Use (21 CFR 801 Subpart C)
PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)
Concurrence of CDRH, Office of Device Evaluation (ODE)
Luddi Cole
Division Sign-Off
Office of In Vitro Diagnostic Device Evaluation and Safety
510(k) K033106
Page 1 of 1